Trial Profile
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Pfizer
- 15 Jun 2023 Results of post-hoc pooled analysis of B1871006 (NCT00261846), B1871007 (NCT00811070), B1871039 (NCT02228382, BYOND) B1871048 (NCT03128411), B1871008 (NCT00574873) & (B1871040, NCT01903733) assessing effect of BMI on the safety of bosutinib in patients with previously treated or newly diagnosed CML, presented at the 28th Congress of the European Haematology Association.
- 01 Dec 2022 Results assessing the the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 60) with newly diagnosed chronic-phase chronic myeloid leukemia published in the International Journal of Hematology
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition